Skip to main content

Vaxcyte, Inc 8-K, filed Nov 4, 2026

Vaxcyte, Inc. (PCVX)

8-K 2026-11-04 For: 2026-11-04
View Original
Added on November 04, 2026

About this 8-K

Vaxcyte, Inc filed this 8-K on November 4, 2026.

Vaxcyte reported that VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial. Third-quarter net loss was $297.1 million, while cash, cash equivalents and investments totaled $2,264.4 million as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits